Medicines optimisation key therapeutic topics-integrated process statement
This integrated process statement relates to the document 'Medicines optimisation: key therapeutic topics' (hereafter referred to as key therapeutic topics). It has been produced to explain how key therapeutic topics are developed. It provides an overview of the key process and principles,...
National Institute for Health and Care Excellence (NICE)
2013, May 7, 2013
|Series:||Process and methods guides
|Collection:||National Center for Biotechnology Information - Collection details see MPG.ReNa|
|Summary:||This integrated process statement relates to the document 'Medicines optimisation: key therapeutic topics' (hereafter referred to as key therapeutic topics). It has been produced to explain how key therapeutic topics are developed. It provides an overview of the key process and principles, and describes all stages of the development of key therapeutic topics. These procedures are designed to ensure that a robust, quality-assured document is developed in an open, transparent and timely way, with appropriate input from key groups. This process statement uses the NICE Implementation Support Tool process as an overarching guide to the principles of its development. The NICE Medicines and Prescribing Centre provides advice and support for delivering safety, efficiency and effectiveness in the use of medicines. The Medicines and Prescribing Centre is responsible for developing key therapeutic topics, which are published as implementation tools.|
The NICE Medicines and Prescribing Centre has been working since autumn 2010 to support the Department of Health and NHS England with Medicines Optimisation (formerly under the QIPP medicines use and procurement workstream). QIPP was a large-scale transformational programme or the NHS with national work streams designed to support the NHS to achieve a number of quality and productivity challenges. The QIPP medicines use and procurement work stream aimed to ensure that value for money was further enhanced while quality of care was maintained or improved, by optimising the use of medicines. Medicines optimisation is defined as 'a person-centred approach to safe and effective medicines use, to ensure people obtain the best possible outcomes from their medicines. Medicines optimisation applies to people who may or may not take their medicines effectively.
This is because of technical limitations with currently available prescribing data which, on occasion, preclude the production of meaningful comparators. Importantly, key therapeutic topics do not constitute formal NICE guidance and this is clearly stated on the publication
Shared decision-making is an essential part of evidence-based medicine, seeking to use the best available evidence to guide decisions about the care of the individual patient, taking into account their needs, preferences and values'. The key therapeutic topics summarise the evidence base on topics identified to support medicines optimisation. These are usually therapeutic areas where there are potential opportunities for maintaining or improving quality and improving value. Releasing resources from 1 area of healthcare while maintaining or improving quality of care means those resources are available, for example, for the prescribing of innovative medicines. The Health and Social Care Information Centre (HSCIC) is responsible for the development of prescribing comparators for these therapeutic topics. These are developed under a separate process by the HSCIC. Not every therapeutic topic has a comparator.
|Physical Description:||1 PDF file (14 pages)|